Breaking Down SG&A Expenses: Novo Nordisk A/S vs Dynavax Technologies Corporation

SG&A Expenses: Novo Nordisk vs Dynavax - A Decade of Growth

__timestampDynavax Technologies CorporationNovo Nordisk A/S
Wednesday, January 1, 20141776300026760000000
Thursday, January 1, 20152218000032169000000
Friday, January 1, 20163725700032339000000
Sunday, January 1, 20172736700032124000000
Monday, January 1, 20186477000033313000000
Tuesday, January 1, 20197498600035830000000
Wednesday, January 1, 20207925600036886000000
Friday, January 1, 202110015600041058000000
Saturday, January 1, 202213140800050684000000
Sunday, January 1, 202315294600061598000000
Monday, January 1, 202467377000000
Loading chart...

Unleashing insights

A Tale of Two Companies: SG&A Expenses in Focus

In the world of pharmaceuticals, the strategic allocation of Selling, General, and Administrative (SG&A) expenses can be a game-changer. Novo Nordisk A/S, a Danish multinational, and Dynavax Technologies Corporation, a U.S.-based biotech firm, offer a fascinating contrast in their financial strategies from 2014 to 2023. Novo Nordisk's SG&A expenses have consistently dwarfed those of Dynavax, reflecting its expansive global operations and marketing efforts. In 2023, Novo Nordisk's SG&A expenses were approximately 400 times greater than Dynavax's, highlighting its dominant market presence. Over the decade, Novo Nordisk's expenses grew by about 130%, while Dynavax saw an impressive 760% increase, albeit from a much smaller base. This growth trajectory underscores Dynavax's aggressive push to expand its market footprint. Understanding these financial dynamics provides valuable insights into each company's strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025